<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252056</url>
  </required_header>
  <id_info>
    <org_study_id>260-09-805-01</org_study_id>
    <nct_id>NCT01252056</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of Cilostazol and Probucol in combination on patients with diabetic&#xD;
      nephropathy is better than the single use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study is:&#xD;
&#xD;
        1. To evaluate the efficacy of Probucol on deferring nephropathy development of the&#xD;
           patients with diabetic nephropathy (including: the change value of urine albumin from&#xD;
           the baseline, the rate of the patients with serum creatinine reaching a doubling of the&#xD;
           base-line serum creatinine, the rate of the hemodialysis-free survival).&#xD;
&#xD;
        2. To evaluate the efficacy of Cliostazol and Probucol in combination on deferring&#xD;
           nephropathy development of the patients with diabetic nephropathy&#xD;
&#xD;
        3. To evaluate the efficacy of Cilostazol and Probucol in combination on atherosclerosis&#xD;
           related biomarkers change. Atherosclerosis related biomarkers include:(a)Endothelium&#xD;
           parameter: ICAM-1, vWF, VCAM-1,and McP-1. (b)Finolysis parameter: TM. (c)Inflammation&#xD;
           parameter: Hs-CRP; IL-6. (d)Oxidation parameter: Ox-LDL, 8-OHdG. (e)Lipid parameter: TC,&#xD;
           LDL-C, HDL-C, TG.&#xD;
&#xD;
        4. To evaluate the efficacy of Cilostazol and Probucol in combination on the progress of&#xD;
           carotid intima-media thickness (IMT) on patients with diabetic nephropathy.&#xD;
&#xD;
        5. To evaluate the safety of Cilostazol and Probucol in combination on the patients with&#xD;
           diabetic nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nephropathy development</measure>
    <time_frame>96W</time_frame>
    <description>After 96-week treatment, compare the efficacy between Probucol group and group control group on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IMT</measure>
    <time_frame>48 and 96W</time_frame>
    <description>After 48-week and 96-week treatment, compare the change value of IMT from the baseline among 3 modality groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherosclerosis related biomarkers</measure>
    <time_frame>48 and 96W</time_frame>
    <description>After 12-week, 48-week and 96-week treatment, compare the change value of atherosclerosis related biomarkers from the baseline among 3 modality groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nephropathy development</measure>
    <time_frame>48 and 96W</time_frame>
    <description>1. After 48-week and 96-week treatment, compare the efficacy among 3 modality groups on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>96W</time_frame>
    <description>Incidence of adverse events, clinically relevant abnormal laboratory results before and after treatment (including hemotology, biochemistry, routine urine analysis and glycosylated hemoglobin), abnormal findings of vital sign, physical examination, and 12-lead ECG results</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probucol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probucol treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probucol and Cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>250mg,Bid</description>
    <arm_group_label>Probucol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol and Cilostazol</intervention_name>
    <description>50-100mg,Bid</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 40~75 years old&#xD;
&#xD;
          -  Type 2 diabetes mellitus above 6 months&#xD;
&#xD;
          -  HbA1c ≤8%&#xD;
&#xD;
          -  Twice (above 2-week interval) confirmed urinary albumin at 30-3000µg/mg.cre&#xD;
&#xD;
          -  Receive routine dosage ACEI or ARB treatment above 2 months, and the dosage has been&#xD;
             fixed for at least 1 month&#xD;
&#xD;
          -  LDL-C&gt;100 mg/dL (2.60 mmol/L) and/ or hyperlipidemia patients with Statins treatment&#xD;
&#xD;
          -  Free will to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an allergic history to investigational drugs&#xD;
&#xD;
          -  Receive antilipemic agents (except Statins) within the latest 2 months, including&#xD;
             Probucol&#xD;
&#xD;
          -  Receive antiplatelet or anticoagulation agents (except Aspirin) within the latest 2&#xD;
             months, including Cilostazol&#xD;
&#xD;
          -  Rapid progression of nephropathy within the latest 3 months&#xD;
&#xD;
          -  Kidney disease caused by other reasons according to medical history&#xD;
&#xD;
          -  Serum potassium level less than 3.5 mEq/L or more than 5.5 mEq/L&#xD;
&#xD;
          -  Hemorrhagic tendency or hemorrhagic disease (such as alimentary tract hemorrhage,&#xD;
             active fundus hemorrhage, etc.)&#xD;
&#xD;
          -  Has a myocardial infarction, angina pectoris, or cerebral infarction within the latest&#xD;
             3 months&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Pregnant, potentially pregnant, or lactating woman&#xD;
&#xD;
          -  Severe hepatic inadequacy (AST or ALT is 2.5 times higher than the upper limit of the&#xD;
             normal value range)&#xD;
&#xD;
          -  Serum creatinine level is 1.5 times higher than the upper limit of the normal value&#xD;
             range&#xD;
&#xD;
          -  Persistent or hardly controlled hypertension (such as malignant hypertension, SBP≥170&#xD;
             mmHg and/ or DBP≥100 mmHg)&#xD;
&#xD;
          -  Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular&#xD;
             contractions)&#xD;
&#xD;
          -  Has a medical history of cardiac syncope or primary syncope&#xD;
&#xD;
          -  Has condition that may prolong QT interval (such as congenital long QT syndrome,&#xD;
             taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.), or for&#xD;
             man QT interval&gt;450msec, for woman QT interval&gt;470msec&#xD;
&#xD;
          -  Has severe complication (such as diabetes mellitus ketoacidosis, nonketotic&#xD;
             hyperosmolar diabetic coma, malignant tumor, severe anaemia, severe hematologic&#xD;
             diseases, etc.)&#xD;
&#xD;
          -  Register other clinical trials within the latest 3 months&#xD;
&#xD;
          -  Other conditions that would be excluded from this study according to doctors'judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohui Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Universuty First Hospital</name>
      <address>
        <city>Beijng</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>May 7, 2013</last_update_submitted>
  <last_update_submitted_qc>May 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

